- Home
- PRAX vs NICE Comparison
PRAX vs NICE Comparison
Compare PRAX & NICE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRAX | NICE |
|---|---|---|
| Founded | 2015 | 1986 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 7.2B |
| IPO Year | 2020 | 1996 |
Fundamental Metrics
Financial Performance| Metric | PRAX | NICE |
|---|---|---|
| Price | $280.54 | $116.06 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 13 |
| Target Price | ★ $374.64 | $162.31 |
| AVG Volume (30 Days) | 580.3K | ★ 638.2K |
| Earning Date | 02-27-2026 | 02-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 35.79 |
| EPS | N/A | ★ 8.79 |
| Revenue | $7,463,000.00 | ★ $2,880,503,000.00 |
| Revenue This Year | N/A | $9.57 |
| Revenue Next Year | $12,467.71 | $8.07 |
| P/E Ratio | ★ N/A | $13.27 |
| Revenue Growth | ★ 364.98 | 9.24 |
| 52 Week Low | $26.70 | $99.00 |
| 52 Week High | $317.72 | $180.61 |
Technical Indicators
Market Signals| Indicator | PRAX | NICE |
|---|---|---|
| Relative Strength Index (RSI) | 56.56 | 56.85 |
| Support Level | $266.93 | $114.35 |
| Resistance Level | $305.21 | $118.25 |
| Average True Range (ATR) | 14.88 | 2.53 |
| MACD | -4.29 | 0.77 |
| Stochastic Oscillator | 27.40 | 75.21 |
Price Performance
Historical ComparisonAbout PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
About NICE NICE Ltd
Nice is an enterprise software company that serves the customer engagement and financial crime and compliance markets. Software is deployed primarily on the cloud, but also on premises. Within customer engagement, Nice's CXone is the leading CCaaS platform providing solutions such as call routing, interactive voice response, digital self-service, and workforce engagement management. Within financial crime and compliance, Nice offers risk and investigation management, fraud prevention, anti-money-laundering, and compliance solutions.